Last reviewed · How we verify

NCT01896336

Efficacy and Safety of 5 mg Sublingual Zolpidem vs 10mg Oral Zolpidem in the Induction and Maintenance of Sleep in Patients With Primary Insomnia

Completed Phase 4 Last updated 24 February 2021
What this trial tests

Phase 4 trial testing Zolpidem Hemitartrate in Primary Insomnia in 67 participants. Completed in 10 December 2013.

Timeline
18 February 2013
Primary endpoint
11 November 2013
10 December 2013

Quick facts

Lead sponsorEMS
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment67
Start date18 February 2013
Primary completion11 November 2013
Estimated completion10 December 2013
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

EMS — full company profile →

Who can join

Adults 20 to 64, any sex, with Primary Insomnia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of sublingual zolpidem presentation 5 mg in the induction of sleep in patients with primary insomnia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial.
    Castro LS, Otuyama LJ, Fumo-Dos-Santos C, Tufik S, et al · · 2020 · cited 6× · PMID 31859791 · DOI 10.1590/1516-4446-2019-0389

Verify or expand the search:

Other recruiting trials for Primary Insomnia

Currently open trials in the same condition.

Other EMS trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01896336.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing